The diagnosis of CNL also requires that molecular testing be negative for defining markers of alternate neoplasms including not only the BCR-ABL1 fusion gene but also rearrangements in PDGFRA/B or FGFR1, characteristic of eosinophilic leukemia. This evidence concerns the gene PDGFRA and Chronic Eosinophilic Leukemia, Not Otherwise Specified.